HMGBiotech is a biotech company founded by Marco E. Bianchi, a leading scientist in the HMGB field.
HMGBiotech is the only producer of quality-controlled redox variants of HMGB1. The company provides reagents, services and ideas to other researchers and companies active in this promising field and also helps the Bianchi lab in developing assays and reagents.
HMGB1 is a component of the cell nucleus, with multiple functions in the organization and expression of the genome. When a cell dies because of an insult (a virus, a mechanical or chemical trauma, poisoning) HMGB1 is released and is picked up by receptors in nearby cells. In addition, cells under severe stress secrete HMGB1 even before dying. Surviving cells mount a firstline response -inflammation- and try to replace the dead cells and reconstruct the damaged tissue. HMGB1 promotes recovery and regeneration, for example of the heart after infarction. However, too much HMGB1 is associated to sepsis (excessive inflammation leading to acute distress and eventually death), arthritis, atherosclerosis, and cancer metastasis.
HMGBiotech has R&D and production unit within Ospedale San Raffaele, one of the leading research institutes in Italy as per volume and quality of scientific output.